| Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease L Jostins, S Ripke, RK Weersma, RH Duerr, DP McGovern, KY Hui, ... Nature 491 (7422), 119-124, 2012 | 5126 | 2012 |
| Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease JC Barrett, S Hansoul, DL Nicolae, JH Cho, RH Duerr, JD Rioux, SR Brant, ... Nature genetics 40 (8), 955-962, 2008 | 3223 | 2008 |
| Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci A Franke, DPB McGovern, JC Barrett, K Wang, GL Radford-Smith, ... Nature genetics 42 (12), 1118-1125, 2010 | 3131 | 2010 |
| Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the number of confirmed associations to 47 CA Anderson, G Boucher, CW Lees, A Franke, M D'Amato, KD Taylor, ... Nature genetics 43 (3), 246-252, 2011 | 1701 | 2011 |
| Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial G D'Haens, F Baert, G Van Assche, P Caenepeel, P Vergauwe, ... The Lancet 371 (9613), 660-667, 2008 | 1533* | 2008 |
| Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease F Baert, L Moortgat, G Van Assche, P Caenepeel, P Vergauwe, M De Vos, ... Gastroenterology 138 (2), 463-468, 2010 | 996 | 2010 |
| The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations G Van Assche, A Dignass, W Reinisch, CJ van der Woude, A Sturm, ... Journal of Crohn's and Colitis 4 (1), 63-101, 2010 | 934 | 2010 |
| The first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease M Harbord, V Annese, SR Vavricka, M Allez, M Barreiro-de Acosta, ... Journal of Crohn's and Colitis 10 (3), 239-254, 2016 | 804 | 2016 |
| Novel Crohn Disease Locus Identified by Genome-Wide Association Maps to a Gene Desert on 5p13.1 and Modulates Expression of PTGER4 C Libioulle, E Louis, S Hansoul, C Sandor, F Farnir, D Franchimont, ... PLoS genetics 3 (4), e58, 2007 | 684 | 2007 |
| Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial D Laharie, A Bourreille, J Branche, M Allez, Y Bouhnik, J Filippi, F Zerbib, ... The Lancet 380 (9857), 1909-1915, 2012 | 643 | 2012 |
| International IBD Genetics Consortium (IIBDGC). Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease L Jostins, S Ripke, RK Weersma, RH Duerr, DP McGovern, KY Hui, ... Nature 491 (7422), 119-124, 2012 | 621 | 2012 |
| Heterogeneity of the gut microbiome in mice: guidelines for optimizing experimental design D Laukens, BM Brinkman, J Raes, M De Vos, P Vandenabeele FEMS microbiology reviews 40 (1), 117-132, 2016 | 401 | 2016 |
| Butyrate-producing bacteria supplemented in vitro to Crohn’s disease patient microbiota increased butyrate production and enhanced intestinal epithelial barrier … A Geirnaert, M Calatayud, C Grootaert, D Laukens, S Devriese, ... Scientific reports 7 (1), 11450, 2017 | 383 | 2017 |
| Spondyloarthropathy is underestimated in inflammatory bowel disease: prevalence and HLA association. K De Vlam, H Mielants, C Cuvelier, F De Keyser, EM Veys, M De Vos The Journal of rheumatology 27 (12), 2860-2865, 2000 | 379 | 2000 |
| Microscopic gut inflammation in axial spondyloarthritis: a multiparametric predictive model L Van Praet, FE Van den Bosch, P Jacques, P Carron, L Jans, R Colman, ... Annals of the rheumatic diseases 72 (3), 414-417, 2013 | 342 | 2013 |
| High-density mapping of the MHC identifies a shared role for HLA-DRB1* 01: 03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis P Goyette, G Boucher, D Mallon, E Ellinghaus, L Jostins, H Huang, ... Nature genetics 47 (2), 172-179, 2015 | 329 | 2015 |
| A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with-308 TNF gene polymorphism E Louis, S Vermeire, P Rutgeerts, M De Vos, A Van Gossum, P Pescatore, ... Scandinavian journal of gastroenterology 37 (7), 2002 | 312 | 2002 |
| Increasing infliximab dose based on symptoms, biomarkers, and serum drug concentrations does not increase clinical, endoscopic, and corticosteroid-free remission in patients … G D’Haens, S Vermeire, G Lambrecht, F Baert, P Bossuyt, B Pariente, ... Gastroenterology 154 (5), 1343-1351. e1, 2018 | 301 | 2018 |
| Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms F Van den Bosch, E Kruithof, M De Vos, F De Keyser, H Mielants The Lancet 356 (9244), 1821-1822, 2000 | 296 | 2000 |
| Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease E Louis, Z El Ghoul, S Vermeire, S Dall'Ozzo, P Rutgeerts, G Paintaud, ... Alimentary pharmacology & therapeutics 19 (5), 511-519, 2004 | 278 | 2004 |
